Free Trial Free TrialFree Trial

More results...

Filter by Content types
Regulatory databases
Regulatory reports
Market reports
News analysis
Filter by Geography
Africa
Asia
Australasia
Europe
United Kingdom
North America
United States
South America

Alerts LATEST ALERTS

  • United States - Washington Pre-employment cannabis testing set to become illegal…
  • Europe CBD and cosmetics – EU working group works on…
  • Belgium Cannabinoid pouches banned by decree…
  • Delaware - United States Senate approves legal framework for adult possession of cannabis…
  • United States - Virginia Cannabis advertising becomes a Class 1 misdemeanour…
  • Kazakhstan ‘Narcotic’ cannabis banned from medical use by decree…
  • Canada Consultation opens on possible changes to cannabis regulations…
  • Turkey Grain Board takes over responsibility for cannabis growing…
  • Georgia US - United States Limit on medical cannabis licences raised…
  • Mississippi - United States Topical hemp products exempted from medical cannabis rules…
  • North Dakota - United States Medical cannabis bill relating to hospice care signed by governor…
  • Lithuania THC to be banned in all tobacco products as of 1st April…
View all
News analysis

FDA gathers in opposing strong views and cannabis-related anecdotes

Written by || 25th July 2019 || News analysis | Health and science | Policy and Politics | Regulation and legislation | North America United States

The US Food and Drug Administration (FDA)’s request for comments on regulating cannabis-related products drew 4492 responses covering a dizzying array of views ...

Benefits of subscription plans:

  • Stay informed of any legal and market change in the sector that impacts your organization
  • Maximise resources by getting market and legal data analysis daily in one place
  • Make smart decisions by understanding how the regulatory and market landscape evolves
  • Anticipate risks in your decisions by monitoring regulatory changes that impact your organization

Need help?

Contact a sales representative right now and don’t wait

Email us

Related contents
FDA’s big meeting leaves long road ahead shrouded in uncertainty
More regulatory doubts over CBD in US as FDA commissioner steps down
FDA considers the question of routes to market for non-pharma CBD

CannIntelligence.com provides independent, in-depth regulatory and market data and intelligence for the global cannabis and cannabinoid sector.

© 2023 Tamarind Media Limited (T/A CannIntelligence)
CannIntelligence does not provide legal, strategic or investment advice. Tamarind Media Limited, the publisher of CannIntelligence, does not accept any liability or responsibility for information or views published.